Cargando…

Comparison of disease activity measures in early psoriatic arthritis in usual care

OBJECTIVES: To compare responsiveness and longitudinal validity of Disease Activity Score 28 (DAS28), Disease Activity index for PSoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic ArthritiS Disease Activity Score (PASDAS), GRAppa Composite scorE (GRACE) and Mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wervers, Kim, Luime, Jolanda J, Tchetverikov, Ilja, Gerards, Andreas H, Kok, Marc R, Appels, Cathelijne W Y, van der Graaff, Wiebo L, van Groenendael, Johannes H L M, Korswagen, Lindy-Anne, Veris-van Dieren, Josien J, Hazes, Johanna M W, Vis, Marijn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032073/
https://www.ncbi.nlm.nih.gov/pubmed/31211399
http://dx.doi.org/10.1093/rheumatology/kez215
_version_ 1783499496817164288
author Wervers, Kim
Luime, Jolanda J
Tchetverikov, Ilja
Gerards, Andreas H
Kok, Marc R
Appels, Cathelijne W Y
van der Graaff, Wiebo L
van Groenendael, Johannes H L M
Korswagen, Lindy-Anne
Veris-van Dieren, Josien J
Hazes, Johanna M W
Vis, Marijn
author_facet Wervers, Kim
Luime, Jolanda J
Tchetverikov, Ilja
Gerards, Andreas H
Kok, Marc R
Appels, Cathelijne W Y
van der Graaff, Wiebo L
van Groenendael, Johannes H L M
Korswagen, Lindy-Anne
Veris-van Dieren, Josien J
Hazes, Johanna M W
Vis, Marijn
author_sort Wervers, Kim
collection PubMed
description OBJECTIVES: To compare responsiveness and longitudinal validity of Disease Activity Score 28 (DAS28), Disease Activity index for PSoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic ArthritiS Disease Activity Score (PASDAS), GRAppa Composite scorE (GRACE) and Minimal Disease Activity (MDA) in usual care PsA patients, within 1 year after diagnosis. METHODS: Data collected in the Dutch southwest early PsA cohort (DEPAR) were used. Responsiveness was assessed using effect size (ES), standardized response mean (SRM), and discrimination between different general health states. Longitudinal validity was tested using mixed models with outcomes health-related quality of life (HRQOL), productivity and disability. RESULTS: Responsiveness was highest for PASDAS, with ES 1.00 and SRM 0.95, lowest for DAPSA, with ES 0.73 and SRM 0.71, and in between for DAS28, CPDAI and GRACE. Differences in general health were best discriminated with PASDAS and GRACE. Patients reporting stable or worsening general health could not be distinguished by DAS28 or CPDAI. Discrimination was better using DAPSA, but worse than when using PASDAS and GRACE. Longitudinal evolvement of HRQOL and productivity had the highest association with low disease activity according to GRACE, followed by PASDAS, MDA, DAPSA, DAS28, with the lowest association for CPDAI. CONCLUSION: PASDAS and GRACE were superior with respect to responsiveness, and together with MDA best related to longitudinal evolvement of HRQOL, productivity and disability. Responsiveness and longitudinal validity of most outcomes were inferior for DAS28, DAPSA and CPDAI. As alternatives to the continuous measure DAPSA, use of PASDAS or GRACE should be considered.
format Online
Article
Text
id pubmed-7032073
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-70320732020-02-25 Comparison of disease activity measures in early psoriatic arthritis in usual care Wervers, Kim Luime, Jolanda J Tchetverikov, Ilja Gerards, Andreas H Kok, Marc R Appels, Cathelijne W Y van der Graaff, Wiebo L van Groenendael, Johannes H L M Korswagen, Lindy-Anne Veris-van Dieren, Josien J Hazes, Johanna M W Vis, Marijn Rheumatology (Oxford) Clinical Science OBJECTIVES: To compare responsiveness and longitudinal validity of Disease Activity Score 28 (DAS28), Disease Activity index for PSoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic ArthritiS Disease Activity Score (PASDAS), GRAppa Composite scorE (GRACE) and Minimal Disease Activity (MDA) in usual care PsA patients, within 1 year after diagnosis. METHODS: Data collected in the Dutch southwest early PsA cohort (DEPAR) were used. Responsiveness was assessed using effect size (ES), standardized response mean (SRM), and discrimination between different general health states. Longitudinal validity was tested using mixed models with outcomes health-related quality of life (HRQOL), productivity and disability. RESULTS: Responsiveness was highest for PASDAS, with ES 1.00 and SRM 0.95, lowest for DAPSA, with ES 0.73 and SRM 0.71, and in between for DAS28, CPDAI and GRACE. Differences in general health were best discriminated with PASDAS and GRACE. Patients reporting stable or worsening general health could not be distinguished by DAS28 or CPDAI. Discrimination was better using DAPSA, but worse than when using PASDAS and GRACE. Longitudinal evolvement of HRQOL and productivity had the highest association with low disease activity according to GRACE, followed by PASDAS, MDA, DAPSA, DAS28, with the lowest association for CPDAI. CONCLUSION: PASDAS and GRACE were superior with respect to responsiveness, and together with MDA best related to longitudinal evolvement of HRQOL, productivity and disability. Responsiveness and longitudinal validity of most outcomes were inferior for DAS28, DAPSA and CPDAI. As alternatives to the continuous measure DAPSA, use of PASDAS or GRACE should be considered. Oxford University Press 2019-12 2019-06-18 /pmc/articles/PMC7032073/ /pubmed/31211399 http://dx.doi.org/10.1093/rheumatology/kez215 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Science
Wervers, Kim
Luime, Jolanda J
Tchetverikov, Ilja
Gerards, Andreas H
Kok, Marc R
Appels, Cathelijne W Y
van der Graaff, Wiebo L
van Groenendael, Johannes H L M
Korswagen, Lindy-Anne
Veris-van Dieren, Josien J
Hazes, Johanna M W
Vis, Marijn
Comparison of disease activity measures in early psoriatic arthritis in usual care
title Comparison of disease activity measures in early psoriatic arthritis in usual care
title_full Comparison of disease activity measures in early psoriatic arthritis in usual care
title_fullStr Comparison of disease activity measures in early psoriatic arthritis in usual care
title_full_unstemmed Comparison of disease activity measures in early psoriatic arthritis in usual care
title_short Comparison of disease activity measures in early psoriatic arthritis in usual care
title_sort comparison of disease activity measures in early psoriatic arthritis in usual care
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032073/
https://www.ncbi.nlm.nih.gov/pubmed/31211399
http://dx.doi.org/10.1093/rheumatology/kez215
work_keys_str_mv AT werverskim comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT luimejolandaj comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT tchetverikovilja comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT gerardsandreash comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT kokmarcr comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT appelscathelijnewy comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT vandergraaffwiebol comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT vangroenendaeljohanneshlm comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT korswagenlindyanne comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT verisvandierenjosienj comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT hazesjohannamw comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT vismarijn comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare
AT comparisonofdiseaseactivitymeasuresinearlypsoriaticarthritisinusualcare